JP2024520788A5 - - Google Patents

Info

Publication number
JP2024520788A5
JP2024520788A5 JP2023575713A JP2023575713A JP2024520788A5 JP 2024520788 A5 JP2024520788 A5 JP 2024520788A5 JP 2023575713 A JP2023575713 A JP 2023575713A JP 2023575713 A JP2023575713 A JP 2023575713A JP 2024520788 A5 JP2024520788 A5 JP 2024520788A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
aqueous solution
subject
bumetanide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023575713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520788A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/032862 external-priority patent/WO2022261344A1/en
Publication of JP2024520788A publication Critical patent/JP2024520788A/ja
Publication of JP2024520788A5 publication Critical patent/JP2024520788A5/ja
Pending legal-status Critical Current

Links

JP2023575713A 2021-06-09 2022-06-09 経口利尿薬に不応性の浮腫を処置するための皮下製剤及び方法 Pending JP2024520788A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163208863P 2021-06-09 2021-06-09
US63/208,863 2021-06-09
PCT/US2022/032862 WO2022261344A1 (en) 2021-06-09 2022-06-09 Subcutaneous formulation and methods for treating edema refractory to oral diuretics

Publications (2)

Publication Number Publication Date
JP2024520788A JP2024520788A (ja) 2024-05-24
JP2024520788A5 true JP2024520788A5 (https=) 2025-06-16

Family

ID=84425561

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575713A Pending JP2024520788A (ja) 2021-06-09 2022-06-09 経口利尿薬に不応性の浮腫を処置するための皮下製剤及び方法

Country Status (10)

Country Link
US (1) US20240285566A1 (https=)
EP (1) EP4351554A4 (https=)
JP (1) JP2024520788A (https=)
KR (1) KR20240042402A (https=)
CN (1) CN117915905A (https=)
AU (1) AU2022289724A1 (https=)
BR (1) BR112023025880A2 (https=)
CA (1) CA3221710A1 (https=)
IL (1) IL309160A (https=)
WO (1) WO2022261344A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293429A (en) 2019-12-04 2022-07-01 RESQ Pharmaceuticals LLC Methods and preparations for the treatment of edema resistant to oral diuretics

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040105818A1 (en) * 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7906555B2 (en) * 2006-10-26 2011-03-15 Arizona Board Of Regents On Behalf Of The University Of Arizona Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
US20140128469A1 (en) * 2011-05-10 2014-05-08 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
US20210163406A1 (en) * 2018-04-06 2021-06-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs
IL293429A (en) * 2019-12-04 2022-07-01 RESQ Pharmaceuticals LLC Methods and preparations for the treatment of edema resistant to oral diuretics

Similar Documents

Publication Publication Date Title
US20230112834A1 (en) Parenteral formulations of treprostinil
KR950013452B1 (ko) 세포 및 조직 수복제
JP2023505189A5 (https=)
EP1696932B1 (en) Use of treprostinil to improve kidney functions
JP2023002662A5 (https=)
JPH013193A (ja) 細胞、組織修復剤
JP2023088944A5 (https=)
US20050282903A1 (en) Use of Treprostinil to treat neuropathic diabetic foot ulcers
RU2013108857A (ru) Соединения для лечения/профилактики воспалительных глазных заболевний
RU2488393C2 (ru) Жидкие композиции, включающие валсартан
JP2711759B2 (ja) 止瀉剤組成物
US4789660A (en) Insulin administration using methyl and propyl paraben
Ashchi et al. Cardiac complication from use of cocaine and phenylephrine in nasal septoplasty
EP2782564B1 (en) Cysteamine and/or cystamine for treating ischemic injury
Bergeron et al. Myocardial infarction, severe reversible ischemia, and shock following excess thyroid administration in a woman with normal coronary arteries
JP2590156B2 (ja) 経口投与用医薬組成物
JP2024520788A5 (https=)
BG65818B1 (bg) Циклесонид-съдържащ фармацевтичен състав за прилагане върху мукоза
US3621094A (en) Concentrated aqueous liquid antacid compositions containing certain phosphate and gluconate salts
JP2024532957A5 (https=)
JP2023520703A5 (https=)
ES2252751T3 (es) Medicamento para el corazon pulmonar.
WO2023185911A1 (zh) 一种吡啶磺酰胺磷酸酯类化合物在制备抗脑水肿药物中的用途
Lunder et al. SGLT-2 inhibitors: a novelty in the treatment of type 2 diabetes
JPS5846023A (ja) ヒトプロインシユリン製剤